2,525 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,525 shares of the biopharmaceutical company’s stock, valued at approximately $205,000.

Other large investors have also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd boosted its holdings in shares of Gilead Sciences by 7.0% during the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 121 shares during the period. Nilsine Partners LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the 3rd quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. grew its position in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the last quarter. Financial Counselors Inc. grew its holdings in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares during the last quarter. Finally, Revolve Wealth Partners LLC increased its holdings in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after buying an additional 130 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Mizuho dropped their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a report on Thursday, February 22nd. Royal Bank of Canada decreased their target price on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. Cantor Fitzgerald cut their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, UBS Group lowered their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $84.71.

Gilead Sciences Price Performance

NASDAQ GILD opened at $66.76 on Friday. The company has a market cap of $83.12 billion, a PE ratio of 14.84, a price-to-earnings-growth ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm’s 50-day simple moving average is $71.96 and its two-hundred day simple moving average is $76.56. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the company posted $1.67 EPS. Research analysts predict that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 annualized dividend and a yield of 4.61%. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.